感染性腹泻 中国就医指南

Infectious diarrhea is an acute gastrointestinal disorder characterized by frequent, loose, or watery stools caused by pathogenic microorganisms—including bacteria (e.g., Salmonella, Campylobacter, Shigella, Escherichia coli), viruses (e.g., norovirus, rotavirus, adenovirus), and parasites (e.g., Giardia lamblia, Cryptosporidium)—that invade the intestinal mucosa or produce enterotoxins. Pathogenesis involves either direct mucosal invasion leading to inflammation and epithelial damage, or toxin-mediated disruption of ion transport (e.g., cholera toxin activating adenylate cyclase → chloride secretion → osmotic water loss). In some cases, post-infectious complications such as reactive arthritis, Guillain-Barré syndrome (linked to Campylobacter), or irritable bowel syndrome may arise. Globally, infectious diarrhea remains a leading cause of morbidity and mortality—especially among children under five—accounting for an estimated 1.6 million deaths annually, with over 90% occurring in low- and middle-income countries. In China, incidence peaks during summer and early autumn due to warmer temperatures favoring bacterial proliferation and increased consumption of raw or undercooked foods. Risk factors include poor sanitation, inadequate hand hygiene, contaminated food/water, travel to endemic regions, immunocompromised status (e.g., HIV, chemotherapy), antibiotic use (predisposing to Clostridioides difficile infection), and age extremes (infants and elderly). While most cases are self-limiting, severe dehydration, electrolyte imbalances (hypokalemia, metabolic acidosis), acute kidney injury, and sepsis can occur—particularly in vulnerable populations. Beyond physical consequences, infectious diarrhea significantly impairs quality of life: it disrupts work and school attendance, causes anxiety about recurrence or transmission, strains caregiver resources, and may lead to nutritional deficits and growth faltering in children. Chronic or recurrent episodes may erode confidence in daily activities, reduce social engagement, and contribute to long-term gastrointestinal hypersensitivity. Early recognition, appropriate rehydration (oral or intravenous), targeted antimicrobial therapy when indicated (e.g., for dysentery or systemic infection), and supportive care remain cornerstones of management. Prevention emphasizes food safety education, access to clean water, vaccination (e.g., rotavirus vaccine), and antimicrobial stewardship to curb resistance.

# 感染性腹泻治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用人群：轻中度脱水、病程＜7天、无免疫抑制或严重基础病者。

• •补液支持：口服补液盐（ORS）Ⅲ型，3–5元/包；静脉补液（0.9%NaCl+KCl+葡萄糖），含输液费、耗材及护理，280–650元/日。
• •对症药物：蒙脱石散（12–25元/盒）、洛哌丁胺（18–35元/盒）；益生菌（双歧杆菌三联活菌等，45–120元/疗程）。
• •病原学检查：粪便常规+隐血+培养+药敏（含PCR检测如诺如、轮状、产毒大肠杆菌），260–580元。

二、药物/抗感染治疗方案

适用人群：细菌性腹泻（如沙门氏菌、志贺菌、弯曲菌）、重症或高龄/免疫低下者。

• •首选经验用药：阿奇霉素片（35–80元/疗程）或左氧氟沙星注射液（120–220元/疗程）；
• •目标治疗（依据药敏）：头孢曲松钠静滴（260–480元/疗程），总药费+监测费（肝肾功能、电解质复查）合计420–950元。

三、特殊复杂情况处理

适用人群：耐药菌感染（如ESBLs大肠杆菌）、伪膜性肠炎（艰难梭菌相关）、中毒性巨结肠或败血症并发症。

• •万古霉素口服（1,800–3,200元/疗程）或利福昔明（680–1,100元/疗程）；
• •粪菌移植（FMT）治疗复发性艰难梭菌感染：含供体筛选、制备、结肠镜/鼻肠管给药，12,000–22,000元/次（限三甲医院消化内科备案项目）。

四、方案快速选择指南

• •预算≤500元/疗程：ORS+益生菌+粪便快检（推荐基层首诊）；
• •预算1,000–3,000元：静脉补液+靶向抗生素+全套病原学检查（三甲消化科标准路径）；
• •耐药/复发/并发症：优先转诊至三甲消化内科感染亚专业组，启动FMT或多学科会诊（费用≥12,000元）。